The Rohatyn Group Completes Investment in European Contract Research Organization, Optimapharm
May 12, 2020•over 5 years ago
Description
The Rohatyn Group (“TRG”), an emerging markets focused asset management firm, today announced that it has completed an investment in Optimapharm d.d. (“Optimapharm” or the “Company”), to establish a partnership with the company’s founders Gordana Gregurić Čičak and Igor Čičak. Optimapharm is a contract research organization (“CRO”) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.